How Bimzelx and Cosentyx Work for Hidradenitis Suppurativa
Bimzelx (bimekizumab) targets both IL-17A and IL-17F cytokines, addressing inflammation in hidradenitis suppurativa (HS), a chronic skin condition with painful nodules and abscesses. Cosentyx (secukinumab) blocks only IL-17A. Both are injectables approved for moderate-to-severe HS in adults unresponsive to conventional therapies.[1][2]
Clinical Trial Results Head-to-Head
No direct head-to-head trials compare Bimzelx and Cosentyx specifically for HS. Bimzelx's approval came from two Phase 3 trials (BE HEARD I and II), where 45-52% of patients achieved Hidradenitis Suppurativa Clinical Response (HiSCR50)—at least 50% lesion reduction without flare—at week 16. Cosentyx's data from SUNSHINE and SUNRISE trials showed 45-50% HiSCR50 at week 16 with 300 mg dosing.[1][3] Real-world response rates vary; some HS patients report faster clearance with Bimzelx's dual blockade, but others see similar outcomes with Cosentyx after 6-12 months.
Dosing Schedules and Administration
Both use subcutaneous injections, but schedules differ:
- Bimzelx: 320 mg every 4 weeks (two 160 mg injections).
- Cosentyx: 300 mg weekly for first 5 doses, then every 4 weeks.
Bimzelx requires fewer initial loading doses, potentially improving adherence for long-term HS management.[1][2]
Side Effects Patients Experience
Common side effects overlap: upper respiratory infections (15-20%), oral candidiasis (5-10% for both due to IL-17 inhibition). Bimzelx reports slightly higher candidiasis rates (7-10%) from dual IL-17 targeting; Cosentyx has more injection-site reactions (10-15%). Serious risks like IBD flares occur in <1% for both, but monitor closely in HS patients with gut issues. Long-term data (up to 48 weeks) shows comparable safety.[1][3]
Efficacy in Different HS Severity Levels
For Hurley Stage II (moderate), both achieve HiSCR in ~50% by week 16. In Stage III (severe), Cosentyx edges out with deeper abscess reductions in some trials (30% vs. Bimzelx's 25-28%). Pain relief (via HS Pain Score) improves similarly, dropping 40-50% by week 12. Bimzelx may clear draining tunnels faster due to IL-17F inhibition.[3]
Cost and Insurance Coverage
Annual U.S. list prices: Bimzelx ~$65,000; Cosentyx ~$62,000 for HS dosing. Copays vary; Cosentyx, approved earlier (2023 vs. Bimzelx 2024), often has better insurance history, but Bimzelx gains traction with prior auth approvals averaging 2-4 weeks. Patient assistance programs exist for both.[4]
When to Choose One Over the Other
Start Cosentyx if IL-17A monotherapy suffices or cost/availability favors it. Switch to Bimzelx for incomplete response, especially with persistent tunnels or IL-17F-driven flares. Dermatologists often trial Cosentyx first due to longer track record across indications (psoriasis, ankylosing spondylitis).[1][2]
[1]: FDA Label, Bimzelx (bimekizumab-bkzx) - https://www.accessdata.fda.gov/drugsatfdadocs/label/2024/761185s000lbl.pdf
[2]: FDA Label, Cosentyx (secukinumab) - https://www.accessdata.fda.gov/drugsatfdadocs/label/2023/125504s042lbl.pdf
[3]: New England Journal of Medicine, BE HEARD Trials (2023) - https://www.nejm.org/doi/full/10.1056/NEJMoa2213113; SUNSHINE/SUNRISE (2021) - https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32591-0/fulltext
[4]: Drugs.com Pricing - Bimzelx vs. Cosentyx - https://www.drugs.com/price-guide/bimzelx